CN104016877A - 一种苯基乙酰胺类化合物及在制备米拉贝隆中的应用 - Google Patents
一种苯基乙酰胺类化合物及在制备米拉贝隆中的应用 Download PDFInfo
- Publication number
- CN104016877A CN104016877A CN201410261245.XA CN201410261245A CN104016877A CN 104016877 A CN104016877 A CN 104016877A CN 201410261245 A CN201410261245 A CN 201410261245A CN 104016877 A CN104016877 A CN 104016877A
- Authority
- CN
- China
- Prior art keywords
- mirabegron
- amino
- hydroxyl
- formula
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- PBAPPPCECJKMCM-IBGZPJMESA-N mirabegron Chemical compound S1C(N)=NC(CC(=O)NC=2C=CC(CCNC[C@H](O)C=3C=CC=CC=3)=CC=2)=C1 PBAPPPCECJKMCM-IBGZPJMESA-N 0.000 title claims abstract description 32
- 229960001551 mirabegron Drugs 0.000 title claims abstract description 31
- 238000002360 preparation method Methods 0.000 title claims description 20
- FZERHIULMFGESH-UHFFFAOYSA-N N-phenylacetamide Chemical class CC(=O)NC1=CC=CC=C1 FZERHIULMFGESH-UHFFFAOYSA-N 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract description 10
- 238000006243 chemical reaction Methods 0.000 claims description 37
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 24
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 15
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 15
- 150000001875 compounds Chemical class 0.000 claims description 15
- 238000003756 stirring Methods 0.000 claims description 15
- 238000001953 recrystallisation Methods 0.000 claims description 12
- 239000007787 solid Substances 0.000 claims description 12
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 claims description 11
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims description 10
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 claims description 10
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 claims description 9
- 239000012452 mother liquor Substances 0.000 claims description 8
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 claims description 7
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 7
- 238000009833 condensation Methods 0.000 claims description 6
- 230000005494 condensation Effects 0.000 claims description 6
- 239000012280 lithium aluminium hydride Substances 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 6
- IWYDHOAUDWTVEP-SSDOTTSWSA-N (R)-mandelic acid Chemical compound OC(=O)[C@H](O)C1=CC=CC=C1 IWYDHOAUDWTVEP-SSDOTTSWSA-N 0.000 claims description 5
- RAIPHJJURHTUIC-UHFFFAOYSA-N 1,3-thiazol-2-amine Chemical compound NC1=NC=CS1 RAIPHJJURHTUIC-UHFFFAOYSA-N 0.000 claims description 5
- -1 lithium aluminum hydride Chemical compound 0.000 claims description 5
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 4
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 claims description 4
- 229960000549 4-dimethylaminophenol Drugs 0.000 claims description 3
- 239000012964 benzotriazole Substances 0.000 claims description 3
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 claims description 2
- FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 claims description 2
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 claims description 2
- 239000012190 activator Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000012043 crude product Substances 0.000 claims description 2
- 238000002425 crystallisation Methods 0.000 claims description 2
- 230000008025 crystallization Effects 0.000 claims description 2
- XIFJZJPMHNUGRA-UHFFFAOYSA-N n-methyl-4-nitroaniline Chemical compound CNC1=CC=C([N+]([O-])=O)C=C1 XIFJZJPMHNUGRA-UHFFFAOYSA-N 0.000 claims description 2
- 229910052763 palladium Inorganic materials 0.000 claims description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 2
- 238000010992 reflux Methods 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N N-phenyl amine Natural products NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- KZYFQHBRHZCKRY-AAFJCEBUSA-N 1-[(6R)-6-[2-(4-aminophenyl)ethylamino]-1-hydroxycyclohexa-2,4-dien-1-yl]ethanone Chemical compound NC1=CC=C(C=C1)CCN[C@H]1C(C=CC=C1)(C(C)=O)O KZYFQHBRHZCKRY-AAFJCEBUSA-N 0.000 abstract 1
- 238000009776 industrial production Methods 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- LSBDFXRDZJMBSC-UHFFFAOYSA-N 2-phenylacetamide Chemical class NC(=O)CC1=CC=CC=C1 LSBDFXRDZJMBSC-UHFFFAOYSA-N 0.000 description 15
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 238000001291 vacuum drying Methods 0.000 description 9
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 239000012044 organic layer Substances 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 235000019270 ammonium chloride Nutrition 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 4
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 4
- DYCLHZPOADTVKK-UHFFFAOYSA-N 2-(2-azaniumyl-1,3-thiazol-4-yl)acetate Chemical compound NC1=NC(CC(O)=O)=CS1 DYCLHZPOADTVKK-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 206010020853 Hypertonic bladder Diseases 0.000 description 3
- 208000009722 Overactive Urinary Bladder Diseases 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 229960000935 dehydrated alcohol Drugs 0.000 description 3
- 238000003810 ethyl acetate extraction Methods 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- BOKYOFNXTSEUOP-UHFFFAOYSA-N n-methyl-4-nitroaniline;hydrochloride Chemical compound [Cl-].C[NH2+]C1=CC=C([N+]([O-])=O)C=C1 BOKYOFNXTSEUOP-UHFFFAOYSA-N 0.000 description 3
- 208000020629 overactive bladder Diseases 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 238000006722 reduction reaction Methods 0.000 description 3
- 238000010792 warming Methods 0.000 description 3
- JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 2
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
- UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 238000005576 amination reaction Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000007905 drug manufacturing Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229940120393 myrbetriq Drugs 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- FIYYMXYOBLWYQO-UHFFFAOYSA-N ortho-iodylbenzoic acid Chemical compound OC(=O)C1=CC=CC=C1I(=O)=O FIYYMXYOBLWYQO-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229940126158 β3 adrenergic receptor agonist Drugs 0.000 description 1
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410261245.XA CN104016877B (zh) | 2014-06-13 | 2014-06-13 | 一种苯基乙酰胺类化合物及在制备米拉贝隆中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410261245.XA CN104016877B (zh) | 2014-06-13 | 2014-06-13 | 一种苯基乙酰胺类化合物及在制备米拉贝隆中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104016877A true CN104016877A (zh) | 2014-09-03 |
CN104016877B CN104016877B (zh) | 2017-02-15 |
Family
ID=51433932
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410261245.XA Active CN104016877B (zh) | 2014-06-13 | 2014-06-13 | 一种苯基乙酰胺类化合物及在制备米拉贝隆中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104016877B (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105111165A (zh) * | 2015-09-14 | 2015-12-02 | 河南师范大学 | 一种米拉贝隆的制备方法 |
CN106278909A (zh) * | 2016-08-12 | 2017-01-04 | 浙江华海药业股份有限公司 | 一种米拉贝隆中间体的后处理方法 |
CN109456277A (zh) * | 2018-10-29 | 2019-03-12 | 安徽省庆云医药股份有限公司 | 一种米拉贝隆的制备方法 |
CN110862359A (zh) * | 2019-11-19 | 2020-03-06 | 苏州永健生物医药有限公司 | 米拉贝隆的合成方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003037881A1 (fr) * | 2001-10-30 | 2003-05-08 | Yamanouchi Pharmaceutical Co., Ltd. | Cristal a forme $g(a) ou $g(b) d'un derive acetanilinide |
CN100406011C (zh) * | 2002-11-07 | 2008-07-30 | 安斯泰来制药有限公司 | 含乙酸酰基苯胺衍生物作为活性成分的膀胱活动过度的治疗药物 |
JP2011105685A (ja) * | 2009-11-20 | 2011-06-02 | Astellas Pharma Inc | フェネチルアミン化合物の結晶 |
CN103387500A (zh) * | 2012-05-11 | 2013-11-13 | 上海医药工业研究院 | 一种米拉贝隆及其中间体的制备方法 |
-
2014
- 2014-06-13 CN CN201410261245.XA patent/CN104016877B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003037881A1 (fr) * | 2001-10-30 | 2003-05-08 | Yamanouchi Pharmaceutical Co., Ltd. | Cristal a forme $g(a) ou $g(b) d'un derive acetanilinide |
CN100406011C (zh) * | 2002-11-07 | 2008-07-30 | 安斯泰来制药有限公司 | 含乙酸酰基苯胺衍生物作为活性成分的膀胱活动过度的治疗药物 |
JP2011105685A (ja) * | 2009-11-20 | 2011-06-02 | Astellas Pharma Inc | フェネチルアミン化合物の結晶 |
CN103387500A (zh) * | 2012-05-11 | 2013-11-13 | 上海医药工业研究院 | 一种米拉贝隆及其中间体的制备方法 |
Non-Patent Citations (3)
Title |
---|
RISA YAMASHITA等: "Primary Alkylboronic Acids as Highly Active Catalysts for the Dehydrative Amide Condensation of r‑Hydroxycarboxylic Acids", 《ORG. LETT.》 * |
RISA YAMASHITA等: "Primary Alkylboronic Acids as Highly Active Catalysts for the Dehydrative Amide Condensation of r‑Hydroxycarboxylic Acids", 《ORG. LETT.》, vol. 15, no. 14, 26 June 2013 (2013-06-26), pages 11 * |
申泮文等: "《无机化学丛书 第1卷 稀有气体氢碱金属 》", 31 March 2011 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105111165A (zh) * | 2015-09-14 | 2015-12-02 | 河南师范大学 | 一种米拉贝隆的制备方法 |
CN106278909A (zh) * | 2016-08-12 | 2017-01-04 | 浙江华海药业股份有限公司 | 一种米拉贝隆中间体的后处理方法 |
WO2018028679A1 (zh) * | 2016-08-12 | 2018-02-15 | 浙江华海药业股份有限公司 | 一种米拉贝隆中间体的后处理方法 |
CN106278909B (zh) * | 2016-08-12 | 2022-07-15 | 浙江华海药业股份有限公司 | 一种米拉贝隆中间体的后处理方法 |
CN109456277A (zh) * | 2018-10-29 | 2019-03-12 | 安徽省庆云医药股份有限公司 | 一种米拉贝隆的制备方法 |
CN109456277B (zh) * | 2018-10-29 | 2022-04-22 | 安徽省庆云医药股份有限公司 | 一种米拉贝隆的制备方法 |
CN110862359A (zh) * | 2019-11-19 | 2020-03-06 | 苏州永健生物医药有限公司 | 米拉贝隆的合成方法 |
CN110862359B (zh) * | 2019-11-19 | 2022-04-19 | 苏州永健生物医药有限公司 | 米拉贝隆的合成方法 |
Also Published As
Publication number | Publication date |
---|---|
CN104016877B (zh) | 2017-02-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105168205A (zh) | 一种血管紧张素ii受体和脑啡肽酶受体双重抑制剂lcz696的制备方法 | |
CN103910672B (zh) | Vismodegib的制备方法 | |
CN105254589B (zh) | 一种制备心力衰竭药物中间体的方法 | |
CN104016877A (zh) | 一种苯基乙酰胺类化合物及在制备米拉贝隆中的应用 | |
CN108586356A (zh) | 瑞博西尼新中间体及其制备瑞博西尼的合成方法 | |
CN101817795A (zh) | 一种合成缬沙坦的改进方法 | |
WO2013020460A1 (zh) | 一种阿扎那韦的制备方法 | |
CN105503878A (zh) | 一种阿拉格列汀的合成方法 | |
CN109305980B (zh) | 一种硼酸酯化合物、其合成方法及其用途 | |
WO2019019795A1 (zh) | 一种沙库必曲中间体的制备方法 | |
CN103601645B (zh) | 1-(苯乙基氨基)丙烷-2-醇类化合物或其盐的制备方法 | |
CN105669651B (zh) | 一种甲磺酸达比加群酯的制备工艺 | |
CN110655517A (zh) | 一种多替拉韦开环杂质的制备方法及其杂质 | |
CN103467449B (zh) | 一种哌啶衍生物、制备方法及在制备常山酮中的应用 | |
CN105315231A (zh) | 利奈唑胺相关物质的制备方法 | |
CN103922986B (zh) | 维大列汀及其类似物、中间体及其制备方法和应用 | |
CN105130887A (zh) | 一种瑞戈非尼的制备方法 | |
CN105272911B (zh) | 一种对甲苯磺酸索拉非尼的制备方法 | |
CN103694178A (zh) | 一种以含氟基团修饰的苯环为中心的达比加群酯类似物及其合成方法 | |
CN105745191A (zh) | 一种西洛多辛及其中间体的制备方法 | |
CN105418477B (zh) | 降低雷迪帕韦中间体中非对映异构体杂质含量的方法 | |
CN106946724A (zh) | 单胺基抑制剂类中间体2‑乙酰氨基‑2‑苄基丙二酸单乙酯的合成方法 | |
CN103396373A (zh) | 地拉罗司的制备方法及其中间体化合物 | |
CN105859608A (zh) | 一种制备哌马色林半酒石酸盐晶型b的方法 | |
CN107001250A (zh) | 一种制备奥当卡替中间体的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information |
Address after: Park Road in Jiangning District of Nanjing city and Jiangsu province 211100 No. 18 Zijin Fangshan technology innovation special community building 5 903 Applicant after: NANJING HERON PHARMACEUTICAL SCIENCE AND TECHNOLOGY Co.,Ltd. Address before: Park Road in Jiangning District of Nanjing city and Jiangsu province 211100 No. 18 Zijin Fangshan technology innovation special community building 5 903 Applicant before: NANJING HAIRONG PHARMACEUTICAL TECHNOLOGY CO.,LTD. |
|
COR | Change of bibliographic data | ||
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20161206 Address after: Huakang high tech Development Zone, 210061 Nanjing Road, Jiangsu, No. 122 Applicant after: NANJING HAIRONG PHARMACEUTICAL Co.,Ltd. Address before: Park Road in Jiangning District of Nanjing city and Jiangsu province 211100 No. 18 Zijin Fangshan technology innovation special community building 5 903 Applicant before: NANJING HERON PHARMACEUTICAL SCIENCE AND TECHNOLOGY Co.,Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20191122 Address after: 211100 Life Science and Technology Town, No. 568 Longmian Avenue, Jiangning District, Nanjing City, Jiangsu Province, 10 Patentee after: NANJING HERON PHARMACEUTICAL SCIENCE AND TECHNOLOGY Co.,Ltd. Address before: Huakang high tech Development Zone, 210061 Nanjing Road, Jiangsu, No. 122 Patentee before: NANJING HAIRONG PHARMACEUTICAL Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20231229 Address after: The first floor of the office building of Jiangsu Pharmaceutical Research Institute Co., Ltd., No. 26 Majia Street, Gulou District, Nanjing City, Jiangsu Province, 210009 Patentee after: NANJING HENGTONG PHARMACEUTICAL DEVELOPMENT CO.,LTD. Address before: 211100 building 10, life technology Town, 568 longmian Avenue, Jiangning District, Nanjing City, Jiangsu Province Patentee before: NANJING HERON PHARMACEUTICAL SCIENCE AND TECHNOLOGY Co.,Ltd. |
|
TR01 | Transfer of patent right |